Clinical Trials Logo

Filter by:
NCT ID: NCT04631016 Completed - Clinical trials for Chronic Obstructive Pulmonary Disease (COPD)

A Phase II, Randomized, Double-blind, Placebo-controlled Study to Assess MEDI3506 in Participants With COPD and Chronic Bronchitis

FRONTIER-4
Start date: December 14, 2020
Phase: Phase 2
Study type: Interventional

This is a research study to determine the efficacy and safety of investigational drug MEDI3506 for the treatment of adult subjects with Chronic Obstructive Pulmonary Disease and Chronic Bronchitis.

NCT ID: NCT04630951 Completed - Blood Pressure Clinical Trials

Blood Flow Restriction Strength Training in Professional Soccer Players

Start date: October 5, 2020
Phase: N/A
Study type: Interventional

The aims of this clinical study are evaluated the effects of Blood Flood Restriction training on the sport performance of professional and semi-professional soccer players. The participants are twenty male professional and semi-professional soccer players who are playing at RCD Mallorca. Participants will be assigned in two different groups. Both groups develop for six weeks a strength training programs. The first group will base their training in Low Load using Blood Flow Restriction (20-50% of one maximum repetition). The second group will base their training in High Load (60-80% of one maximum repetition). This training program includes three type of exercises in each training session; back squat, single deadlift and barbell hip thrust. Before and after this program the investigators will collect sociodemographic and anthropometrics data. On top of that, the investigators will evaluate the muscle mass, the electrical activity produced by skeletal muscles, the muscle strength and the sprint ability of every participant. Before to the evaluation, the soccer players will warm-up during 15 minutes under the control of the evaluators.

NCT ID: NCT04629508 Completed - Myelofibrosis Clinical Trials

To Assess the Safety, Tolerability and Efficacy of Itacitinib Immediate Release Tablets in Participants With Primary or Secondary Myelofibrosis Who Have Received Prior Ruxolitinib and/or Fedratinib Monotherapy (LIMBER-213)

Start date: July 12, 2021
Phase: Phase 2
Study type: Interventional

This is a 2-part study. In Part 1, participants will be dosed at 2 different dose levels in order to select the RP2D for Part 2 of the study.

NCT ID: NCT04629443 Completed - Clinical trials for Acute Myeloid Leukaemia

Phase I/II Trial of S64315 Plus Azacitidine in Acute Myeloid Leukaemia

Start date: February 17, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to assess the safety, tolerability and clinical activity of the combination S64315 with azacitidine in patients with acute myeloid leukaemia.

NCT ID: NCT04628312 Completed - Clinical trials for Myofascial Pain Syndrome

Foot Plantar Pressure Changes After Plantar Dry Needling

Start date: November 20, 2020
Phase: N/A
Study type: Interventional

The aim of this clinical trial is to check the effects of dry needling in the Flexor digitorum Brevis. Twenty healthy subjects wil be recruited for a quasi-experimental study. Participants will be from 18 to 40 years old, not obese. Participants will be measured before and after bilateral dry neddling in Flexor digitorum Brevis. The investigators will measure static footprint variables. The footprint variables will be divided in bilateral rear foot, bilateral midfoot, bilateral fore foot.

NCT ID: NCT04628299 Completed - Myofascial Pain Clinical Trials

Effects of the Myofascial Induction Technique Versus a Control Laser

Start date: November 16, 2020
Phase: N/A
Study type: Interventional

The objective is to determine the effectiveness of myofascial Induction effects on plantar pressures variables. Forty healthy subjects will be recruited for a simple blind clinical trial. All subjects will be randomly distributed in two different groups: control group (sham Laser) and experimental group (myofascial Induction). Outcome measurements will be foot plantar pressure area (footprint) by a validated platform. Two trials will be recorded before and after intervention in standing position.

NCT ID: NCT04628286 Completed - Myofascial Pain Clinical Trials

Myofascial Induction Effects on Stabilometry Versus Sham Laser

Start date: November 20, 2020
Phase: N/A
Study type: Interventional

The objective is to determine the effectiveness of myofascial induction effects on stabilometric variables. Forty healthy subjects will be recruited for a single blind clinical trial. All subjects will be randomly distributed into two different groups: control group (simulated laser) and experimental group (myofascial induction). Result measurements will be performed in the center of the pressure area (stabilometry) using a validated platform. Two trials will be recorded for each condition (eyes closed and eyes open)

NCT ID: NCT04627025 Completed - Clinical trials for Short Bowel Syndrome

Trial to Evaluate Efficacy and Safety of Apraglutide in SBS-IF

STARS
Start date: January 26, 2021
Phase: Phase 3
Study type: Interventional

The primary objective of the trial is the confirmation of the efficacy of apraglutide to evaluate the efficacy of weekly subcutaneous apraglutide in reducing parenteral support dependency.

NCT ID: NCT04625725 Completed - COVID-19 Clinical Trials

Phase III Double-blind, Placebo-controlled Study of AZD7442 for Pre-exposure Prophylaxis of COVID-19 in Adult.

PROVENT
Start date: November 21, 2020
Phase: Phase 3
Study type: Interventional

This study will assess the safety and efficacy of a single dose of AZD7442(× 2 IM injections) compared to placebo for the prevention of COVID-19.

NCT ID: NCT04625101 Completed - Clinical trials for Epileptic Encephalopathy

Efficacy, Safety, Tolerability, and Pharmacokinetics of NBI-827104 in Pediatric Subjects With Epileptic Encephalopathy With Continuous Spike-and-Wave During Sleep

Start date: April 26, 2021
Phase: Phase 2
Study type: Interventional

This is a phase 2, double-blind study to assess the efficacy, safety, tolerability, and pharmacokinetics of NBI-827104 when administered once daily for 13 weeks in pediatric subjects with Epileptic Encephalopathy with Continuous Spike-and-Wave During Sleep (EECSWS).